Who
Michael A. Metzger
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Syndax Pharmaceuticals; Director, Pyxis Oncology; Director, Cti Biopharma; President & CEO, Regado Biosciences; Director, Response Genetics.
In numbers
- Trades disclosed
- 169
- Buys
- 1
- Sells
- 34
- Bought
- $1,500
- Sold
- $18.0M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Dec 2010
- Last trade
- 8 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $207K32,375 at $6.38 | filing |
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $785K32,375 at $24.24 | filing |
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,375 at $0.00 | filing |
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,375 at $0.00 | filing |
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $207K32,375 at $6.38 | filing |
| 8 Jul 2026filed 9 Jul 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $785K32,375 at $24.24 | filing |
| 1 Jun 2026filed 2 Jun 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $130K6,847 at $18.99 | filing |
| 1 Jun 2026filed 2 Jun 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $130K6,847 at $18.99 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 9 Feb 2026filed 10 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $361K17,159 at $21.03 | filing |
| 9 Feb 2026filed 10 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $361K17,159 at $21.03 | filing |
| 6 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $153K7,412 at $20.62 | filing |
| 6 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $153K7,412 at $20.62 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —144,600 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $9.0M440,000 at $20.43 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $9.0M440,000 at $20.43 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —144,600 at $0.00 | filing |
News
Syndax Pharmaceuticals (SNDX) – Analysts' Recent Ratings ChangesSNDX · dailypolitical.com · 19 Oct 2026Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Michael A. Metzger; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.